These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 29338689)
21. Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer. Kim H; Cho DY; Choi DH; Jung GH; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Gil WH; Kim SW Cancer Res Treat; 2016 Jul; 48(3):955-61. PubMed ID: 26790966 [TBL] [Abstract][Full Text] [Related]
22. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study. Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women. Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955 [TBL] [Abstract][Full Text] [Related]
24. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. Schulz E; Valentin A; Ulz P; Beham-Schmid C; Lind K; Rupp V; Lackner H; Wölfler A; Zebisch A; Olipitz W; Geigl J; Berghold A; Speicher MR; Sill H J Med Genet; 2012 Jul; 49(7):422-8. PubMed ID: 22652532 [TBL] [Abstract][Full Text] [Related]
25. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626 [TBL] [Abstract][Full Text] [Related]
26. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer. Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628 [TBL] [Abstract][Full Text] [Related]
27. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215 [TBL] [Abstract][Full Text] [Related]
28. Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. Silva FC; Lisboa BC; Figueiredo MC; Torrezan GT; Santos EM; Krepischi AC; Rossi BM; Achatz MI; Carraro DM BMC Med Genet; 2014 May; 15():55. PubMed ID: 24884479 [TBL] [Abstract][Full Text] [Related]
29. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families. Castéra L; Harter V; Muller E; Krieger S; Goardon N; Ricou A; Rousselin A; Paimparay G; Legros A; Bruet O; Quesnelle C; Domin F; San C; Brault B; Fouillet R; Abadie C; Béra O; Berthet P; ; Frébourg T; Vaur D Genet Med; 2018 Dec; 20(12):1677-1686. PubMed ID: 29988077 [TBL] [Abstract][Full Text] [Related]
30. Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study. Kim JH; Park S; Park HS; Park JS; Lee ST; Kim SW; Lee JW; Lee MH; Park SK; Noh WC; Choi DH; Han W; Jung SH Sci Rep; 2021 Apr; 11(1):8485. PubMed ID: 33875706 [TBL] [Abstract][Full Text] [Related]
31. Translational advances regarding hereditary breast cancer syndromes. Gage M; Wattendorf D; Henry LR J Surg Oncol; 2012 Apr; 105(5):444-51. PubMed ID: 22441895 [TBL] [Abstract][Full Text] [Related]
32. Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset. Davidson AL; Michailidou K; Parsons MT; Fortuno C; Bolla MK; Wang Q; Dennis J; Naven M; Abubakar M; Ahearn TU; Alonso MR; Andrulis IL; Antoniou AC; Auvinen P; Behrens S; Bermisheva MA; Bogdanova NV; Bojesen SE; Brüning T; Byers HJ; Camp NJ; Campbell A; Castelao JE; Cessna MH; Chang-Claude J; Chanock SJ; Chenevix-Trench G; ; Collée JM; Czene K; Dörk T; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Glendon G; González-Neira A; Grassmann F; Gronwald J; Guénel P; Hadjisavvas A; Haeberle L; Hall P; Hamann U; Hartman M; Ho PJ; Hooning MJ; Hoppe R; Howell A; ; Jakubowska A; Khusnutdinova EK; Kristensen VN; Li J; Lim J; Lindblom A; Liu J; Lophatananon A; Mannermaa A; Mavroudis DA; Mensenkamp AR; Milne RL; Muir KR; Newman WG; Obi N; Panayiotidis MI; Park SK; Park-Simon TW; Peterlongo P; Radice P; Rashid MU; Rhenius V; Saloustros E; Sawyer EJ; Schmidt MK; Seibold P; Shah M; Southey MC; Teo SH; Tomlinson I; Torres D; Truong T; van de Beek I; van der Hout AH; Wendt CC; Dunning AM; Pharoah PDP; Devilee P; Easton DF; James PA; Spurdle AB Am J Hum Genet; 2024 Sep; 111(9):2059-2069. PubMed ID: 39096911 [TBL] [Abstract][Full Text] [Related]
33. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. Ramus SJ; Song H; Dicks E; Tyrer JP; Rosenthal AN; Intermaggio MP; Fraser L; Gentry-Maharaj A; Hayward J; Philpott S; Anderson C; Edlund CK; Conti D; Harrington P; Barrowdale D; Bowtell DD; Alsop K; Mitchell G; ; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Sieh W; McGuire V; Lester J; Bogdanova N; Dürst M; Hillemanns P; ; Odunsi K; Whittemore AS; Karlan BY; Dörk T; Goode EL; Menon U; Jacobs IJ; Antoniou AC; Pharoah PD; Gayther SA J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26315354 [TBL] [Abstract][Full Text] [Related]
34. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449 [TBL] [Abstract][Full Text] [Related]
35. Spectrum of germline pathogenic variants in Brazilian hereditary breast/ovarian cancer cases. Faria JP; Assumpção JG; de Oliveira Matos L; Soardi FC; Bretz GPM; Friedman E; De Marco L Breast Cancer Res Treat; 2024 Oct; 207(3):615-624. PubMed ID: 38874686 [TBL] [Abstract][Full Text] [Related]
37. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593 [TBL] [Abstract][Full Text] [Related]
38. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients. Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190 [TBL] [Abstract][Full Text] [Related]
39. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis. Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809 [TBL] [Abstract][Full Text] [Related]